Interleukin 12 Receptor-United States Market Status and Trend Report 2013-2023
Report Summary
Interleukin 12 Receptor-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Interleukin 12 Receptor industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of Interleukin 12 Receptor 2013-2017, and development forecast 2018-2023
Main market players of Interleukin 12 Receptor in United States, with company and product introduction, position in the Interleukin 12 Receptor market
Market status and development trend of Interleukin 12 Receptor by types and applications
Cost and profit status of Interleukin 12 Receptor, and marketing status
Market growth drivers and challenges
The report segments the United States Interleukin 12 Receptor market as:
United States Interleukin 12 Receptor Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States Interleukin 12 Receptor Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Edodekin Alfa SR
M-9241
LY-3232094
NMIL-121
Others
United States Interleukin 12 Receptor Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
In-Patient
Out-Patient
United States Interleukin 12 Receptor Market: Players Segment Analysis (Company and Product introduction, Interleukin 12 Receptor Sales Volume, Revenue, Price and Gross Margin):
Eli Lilly and Company
Mallinckrodt Plc
Merck KGaA
Neumedicines Inc
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Interleukin 12 Receptor-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Interleukin 12 Receptor industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of Interleukin 12 Receptor 2013-2017, and development forecast 2018-2023
Main market players of Interleukin 12 Receptor in United States, with company and product introduction, position in the Interleukin 12 Receptor market
Market status and development trend of Interleukin 12 Receptor by types and applications
Cost and profit status of Interleukin 12 Receptor, and marketing status
Market growth drivers and challenges
The report segments the United States Interleukin 12 Receptor market as:
United States Interleukin 12 Receptor Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States Interleukin 12 Receptor Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Edodekin Alfa SR
M-9241
LY-3232094
NMIL-121
Others
United States Interleukin 12 Receptor Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
In-Patient
Out-Patient
United States Interleukin 12 Receptor Market: Players Segment Analysis (Company and Product introduction, Interleukin 12 Receptor Sales Volume, Revenue, Price and Gross Margin):
Eli Lilly and Company
Mallinckrodt Plc
Merck KGaA
Neumedicines Inc
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE
1.1 Definition of Proprotein Convertase Subtilisin and Kexin Type 9 in This Report
1.2 Commercial Types of Proprotein Convertase Subtilisin and Kexin Type
1.2.1 SX-PCK9
1.2.2 O-304
1.2.3 K-312
1.2.4 BLSM-201
1.2.5 DCRPCSK-9
1.2.6 Others
1.3 Downstream Application of Proprotein Convertase Subtilisin and Kexin Type
1.3.1 Cardiovascular Disease
1.3.2 Homozugous Familial Hyperchalesterolemia
1.3.3 Liver Disease
1.3.4 Metabolic Syndrome
1.3.5 Others
1.4 Development History of Proprotein Convertase Subtilisin and Kexin Type
1.5 Market Status and Trend of Proprotein Convertase Subtilisin and Kexin Type 9 2013-2023
1.5.1 Global Proprotein Convertase Subtilisin and Kexin Type 9 Market Status and Trend 2013-2023
1.5.2 Regional Proprotein Convertase Subtilisin and Kexin Type 9 Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Proprotein Convertase Subtilisin and Kexin Type 9 2013-2017
2.2 Production Market of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions
2.2.1 Production Volume of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions
2.2.2 Production Value of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions
2.3 Demand Market of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions
2.4 Production and Demand Status of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions
2.4.1 Production and Demand Status of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions 2013-2017
2.4.2 Import and Export Status of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Proprotein Convertase Subtilisin and Kexin Type 9 by Types
3.2 Production Value of Proprotein Convertase Subtilisin and Kexin Type 9 by Types
3.3 Market Forecast of Proprotein Convertase Subtilisin and Kexin Type 9 by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Proprotein Convertase Subtilisin and Kexin Type 9 by Downstream Industry
4.2 Market Forecast of Proprotein Convertase Subtilisin and Kexin Type 9 by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE
5.1 Global Economy Situation and Trend Overview
5.2 Proprotein Convertase Subtilisin and Kexin Type 9 Downstream Industry Situation and Trend Overview
CHAPTER 6 PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE 9 MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Proprotein Convertase Subtilisin and Kexin Type 9 by Major Manufacturers
6.2 Production Value of Proprotein Convertase Subtilisin and Kexin Type 9 by Major Manufacturers
6.3 Basic Information of Proprotein Convertase Subtilisin and Kexin Type 9 by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Proprotein Convertase Subtilisin and Kexin Type 9 Major Manufacturer
6.3.2 Employees and Revenue Level of Proprotein Convertase Subtilisin and Kexin Type 9 Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE 9 MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AFFiRiS AG
7.1.1 Company profile
7.1.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.1.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of AFFiRiS AG
7.2 Betagenon AB
7.2.1 Company profile
7.2.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.2.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Betagenon AB
7.3 Bioleaders Corp
7.3.1 Company profile
7.3.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.3.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Bioleaders Corp
7.4 BioLingus AG
7.4.1 Company profile
7.4.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.4.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of BioLingus AG
7.5 Catabasis Pharmaceuticals Inc
7.5.1 Company profile
7.5.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.5.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Catabasis Pharmaceuticals Inc
7.6 Dicerna Pharmaceuticals Inc
7.6.1 Company profile
7.6.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.6.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Dicerna Pharmaceuticals Inc
7.7 Eli Lilly and Co
7.7.1 Company profile
7.7.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.7.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Eli Lilly and Co
7.8 Ensemble Therapeutics Corp
7.8.1 Company profile
7.8.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.8.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Ensemble Therapeutics Corp
7.9 Kowa Co Ltd
7.9.1 Company profile
7.9.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.9.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Kowa Co Ltd
7.10 Novartis AG
7.10.1 Company profile
7.10.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.10.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Novartis AG
7.11 Pfizer Inc
7.11.1 Company profile
7.11.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.11.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Pfizer Inc
7.12 Regeneron Pharmaceuticals Inc
7.12.1 Company profile
7.12.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.12.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Regeneron Pharmaceuticals Inc
7.13 Serometrix LLC
7.13.1 Company profile
7.13.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.13.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Serometrix LLC
7.14 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
7.14.1 Company profile
7.14.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.14.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
7.15 The Medicines Company
7.15.1 Company profile
7.15.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.15.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of The Medicines Company
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE
8.1 Industry Chain of Proprotein Convertase Subtilisin and Kexin Type
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE
9.1 Cost Structure Analysis of Proprotein Convertase Subtilisin and Kexin Type
9.2 Raw Materials Cost Analysis of Proprotein Convertase Subtilisin and Kexin Type
9.3 Labor Cost Analysis of Proprotein Convertase Subtilisin and Kexin Type
9.4 Manufacturing Expenses Analysis of Proprotein Convertase Subtilisin and Kexin Type
CHAPTER 10 MARKETING STATUS ANALYSIS OF PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Proprotein Convertase Subtilisin and Kexin Type 9 in This Report
1.2 Commercial Types of Proprotein Convertase Subtilisin and Kexin Type
1.2.1 SX-PCK9
1.2.2 O-304
1.2.3 K-312
1.2.4 BLSM-201
1.2.5 DCRPCSK-9
1.2.6 Others
1.3 Downstream Application of Proprotein Convertase Subtilisin and Kexin Type
1.3.1 Cardiovascular Disease
1.3.2 Homozugous Familial Hyperchalesterolemia
1.3.3 Liver Disease
1.3.4 Metabolic Syndrome
1.3.5 Others
1.4 Development History of Proprotein Convertase Subtilisin and Kexin Type
1.5 Market Status and Trend of Proprotein Convertase Subtilisin and Kexin Type 9 2013-2023
1.5.1 Global Proprotein Convertase Subtilisin and Kexin Type 9 Market Status and Trend 2013-2023
1.5.2 Regional Proprotein Convertase Subtilisin and Kexin Type 9 Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Proprotein Convertase Subtilisin and Kexin Type 9 2013-2017
2.2 Production Market of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions
2.2.1 Production Volume of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions
2.2.2 Production Value of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions
2.3 Demand Market of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions
2.4 Production and Demand Status of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions
2.4.1 Production and Demand Status of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions 2013-2017
2.4.2 Import and Export Status of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Proprotein Convertase Subtilisin and Kexin Type 9 by Types
3.2 Production Value of Proprotein Convertase Subtilisin and Kexin Type 9 by Types
3.3 Market Forecast of Proprotein Convertase Subtilisin and Kexin Type 9 by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Proprotein Convertase Subtilisin and Kexin Type 9 by Downstream Industry
4.2 Market Forecast of Proprotein Convertase Subtilisin and Kexin Type 9 by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE
5.1 Global Economy Situation and Trend Overview
5.2 Proprotein Convertase Subtilisin and Kexin Type 9 Downstream Industry Situation and Trend Overview
CHAPTER 6 PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE 9 MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Proprotein Convertase Subtilisin and Kexin Type 9 by Major Manufacturers
6.2 Production Value of Proprotein Convertase Subtilisin and Kexin Type 9 by Major Manufacturers
6.3 Basic Information of Proprotein Convertase Subtilisin and Kexin Type 9 by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Proprotein Convertase Subtilisin and Kexin Type 9 Major Manufacturer
6.3.2 Employees and Revenue Level of Proprotein Convertase Subtilisin and Kexin Type 9 Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE 9 MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AFFiRiS AG
7.1.1 Company profile
7.1.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.1.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of AFFiRiS AG
7.2 Betagenon AB
7.2.1 Company profile
7.2.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.2.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Betagenon AB
7.3 Bioleaders Corp
7.3.1 Company profile
7.3.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.3.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Bioleaders Corp
7.4 BioLingus AG
7.4.1 Company profile
7.4.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.4.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of BioLingus AG
7.5 Catabasis Pharmaceuticals Inc
7.5.1 Company profile
7.5.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.5.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Catabasis Pharmaceuticals Inc
7.6 Dicerna Pharmaceuticals Inc
7.6.1 Company profile
7.6.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.6.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Dicerna Pharmaceuticals Inc
7.7 Eli Lilly and Co
7.7.1 Company profile
7.7.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.7.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Eli Lilly and Co
7.8 Ensemble Therapeutics Corp
7.8.1 Company profile
7.8.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.8.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Ensemble Therapeutics Corp
7.9 Kowa Co Ltd
7.9.1 Company profile
7.9.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.9.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Kowa Co Ltd
7.10 Novartis AG
7.10.1 Company profile
7.10.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.10.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Novartis AG
7.11 Pfizer Inc
7.11.1 Company profile
7.11.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.11.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Pfizer Inc
7.12 Regeneron Pharmaceuticals Inc
7.12.1 Company profile
7.12.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.12.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Regeneron Pharmaceuticals Inc
7.13 Serometrix LLC
7.13.1 Company profile
7.13.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.13.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Serometrix LLC
7.14 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
7.14.1 Company profile
7.14.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.14.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
7.15 The Medicines Company
7.15.1 Company profile
7.15.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
7.15.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of The Medicines Company
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE
8.1 Industry Chain of Proprotein Convertase Subtilisin and Kexin Type
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE
9.1 Cost Structure Analysis of Proprotein Convertase Subtilisin and Kexin Type
9.2 Raw Materials Cost Analysis of Proprotein Convertase Subtilisin and Kexin Type
9.3 Labor Cost Analysis of Proprotein Convertase Subtilisin and Kexin Type
9.4 Manufacturing Expenses Analysis of Proprotein Convertase Subtilisin and Kexin Type
CHAPTER 10 MARKETING STATUS ANALYSIS OF PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
